Latest Ovarian Cancer News

Cleo Diagnostics has raised $5 million to support the U.S. commercial launch of its Pre-Surgical Ovarian Cancer Test and accelerate development of a mass screening test, signaling strong investor confidence in its technology.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Cleo Diagnostics has identified a significantly larger U.S. patient population for its pre-surgical ovarian cancer test, expanding its commercial opportunity ahead of next year’s market entry.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

INOVIQ Limited has raised $11.5 million through a $9.5 million placement and a $2 million share purchase plan to accelerate the development and commercialisation of its EXO-OC ovarian cancer test and exosome therapeutic program.